|
Selvita Completes $ 5.5 Million Private Placement |
|
Thursday, 05 May 2011 |
Kraków, 5th May 2011 - The largest Polish drug discovery company Selvita announced today it has entered into definitive agreements with investors in Poland to sell in a private placement 2,7 million shares of its stock at a price of PLN 5.5 per share, resulting in gross proceeds to the company of PLN 14,85 million ($ 5.5 million).
The capitalization of the company after the issue will be around $ 21 million. Selvita expects its stock to be listed on the Warsaw Stock Exchange NewConnect market in July 2011, subject to regulatory approvals. Proceeds from the financing will be used primarily for the ongoing pre-clinical development of Selvita’s drug candidates including the potentially first in class compounds: SEL24 (Pim kinase inhibitor in oncology), SEL120 (anti-mitotic agent with a novel mechanism of action) and SEL113 (oncology and auto-immune disorders). The company will also expand its lab space for outsourcing of drug discovery projects which is the second pillar of Selvita’s business model.
“We are very happy with the closing of this funding round”, said Pawel Przewiezlikowski, the Chief Executive Officer of Selvita. “From the start of our company in 2007 we have grown a balanced portfolio of projects and services and built a strong customer base in the USA and Europe. Selvita is currently the largest independent drug discovery company in the region. We believe that our hybrid model allows us to offer the best of the Polish science to the global pharmaceutical market and takes full advantage of the country’s scientific base and its large pool of highly skilled researchers.”
The majority of the company shares will continue to be controlled by its management. The largest new shareholder will be Dr. Tadeusz Wesolowski, the founder of Prosper, one of the largest pharmaceutical distributors in Poland (currently part of Neuca group). Dr Wesolowski will also join Selvita’s supervisory board as its Vice President.
The Warsaw-based CC Group served as lead placement agent for the offering with Alior Bank acting as co-placement agent.
About SelvitaSelvita is a Polish, privately-owned, biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS, oncology and autoimmune disorders as well as provision of non-clinical research services. The company was established in 2007 and currently employs 115 people including 40 PhDs. Selvita develops its own innovative drugs, which originate from research at Polish universities and later commercializes them with partners from the pharmaceutical industry. Selvita has currently several projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2012. The service part of the company delivers a comprehensive panel of products and solutions targeted at lowering the cost of, and accelerating, the introduction of new drugs to the market. Since 2010, Selvita is also the owner of BioCentrum, which provides range of in vitro preclinical ADMET services, biochemistry services with special focus on protein engineering and recombinant protein production. Selvita Group has experience in several areas of life sciences, and offers the following types of projects: - Pre-clinical candidate projects derived from research at Polish universities
- Integrated drug discovery projects which include in silico modeling, and synthesis of a target-focused library, lead-optimization and preclinical development.
- Chemistry services, including contract synthesis, synthesis pathway design and optimization, analytical chemistry, as well as computational chemistry services.
- Biology services, including assay development such as ELISA and cytotoxicity assays, spectrophotometric, fluorescence and fluorescence anisotrophy measurements, as well as cell cycle arrest analysis and apoptosis/necrosis identification
- Advanced protein modeling solutions, based on our proprietary protein modeling platform, as well as services in computational chemistry.
Further information about Selvita can be found at http://www.selvita.com.
This press release contains forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as ''anticipates,'' "expects,'' "plans,'' "believes,'' "intends,'' and similar words or phrases. These forward-looking statements include, without limitation, statements related to Selvita’s research programs. Such statements involve risks and uncertainties that could cause Selvita’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, and drug development and commercialization.
Media contact:
Paulina Wolanin
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
tel. : +48 668 111 456 |
|
|
Q2 2011 Selvita Newsletter available now! |
|
|
Q1 2011 Selvita Newsletter available now! |
|
Thursday, 27 January 2011 |
|
The 1st issue of quarterly Selvita newsletter is available now !
|
|
|
Selvita appoints Piotr Prelich as a Vice President of Sales and Marketing |
|
Thursday, 25 November 2010 |
Krakow, Poland, 24 November 2010 - Polish biotechnology company Selvita, announced today the appointment of Mr. Piotr Prelich to the position of Vice President of Sales and Marketing. Mr. Prelich will be responsible for the further establishment of Selvita’s brand in the pharmaceutical preclinical outsourcing market, both in Poland and abroad, as well as for the sales of services offered by Selvita and its subsidiary BioCentrum.
Mr. Piotr Prelich worked from 2007 to 2010 at Invitrogen (Life Technologies group) in the United Kingdom, as Director of Sales and Marketing of the HLA product line (transplantation and diagnostics), for the EMEA region. His previous professional experience includes sales positions in pharmaceutical companies such as Sanofi-Winthrop, Chinoin, Novo Nordisk, Roche Diagnostics and Abbott in Poland and Austria. In 1999-2007 he served as the CEO of Hark Company, specializing in laboratory equipment. He graduated from the Faculty of Medicine, from the Medical University of Lodz.
"Piotr's appointment constitutes for us the commencement of the next phase of Selvita’s expansion in the European market," said Pawel Przewiezlikowski, Selvita’s CEO. "Piotr has extensive contacts in the pharmaceutical and diagnostic industry, experience in building European sales structures in global biotechnology companies, as well as the skills required to manage large outsourcing projects. Strengthening of Selvita Group’s management team by Piotr will enable us to deepen the relationships with large clients from the global pharmaceutical industry. "
"Selvita, probably the largest independent biotechnology research and development company from all new member countries of the European Union, is a valuable partner for domestic and foreign pharmaceutical companies, who want to quickly and cost-effectively introduce innovative drugs to the market," said Piotr Prelich. "My goal at Selvita is to help the company join the group of the world's largest research outsourcing companies over the next few years”.
About Selvita
Selvita Group is a product and solution provider for the pharmaceutical and biotechnology industry from Krakow, Poland. The company was established in 2007, and ever since its mission has been to serve the clients with a comprehensive panel of products and solutions targeted at lowering the cost of, and accelerating, the introduction of new drugs to the market.
Selvita Group employs a highly specialized team of 120 professionals in various fields of life sciences, 40% of them with a PhD degree. We also enjoy a very good cooperation with numerous leading research institutes and universities from Poland as well as Europe and USA.
Since 2010, Selvita is also owner of BioCentrum, which provides in-vitro preclinical ADMET services, biochemistry services with special focus on protein engineering and antibody development.
Selvita Group has experience in several areas of life sciences, and offers the following types of projects:
- Integrated drug discovery projects which include in silico modeling, and synthesis of a target-focused library, lead-optimization and preclinical development.
- chemistry services, including medicinal chemistry, contract synthesis, synthesis pathway design and optimization, analytical chemistry, as well as computational chemistry services.
- biology services, including assay development such as ELISA and cytotoxicity assays, spectrophotometric, fluorescence and fluorescence anisotrophy measurements, as well as cell cycle arrest analysis and apoptosis/necrosis identification.
Media Contact
Natalia Pawela
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
+48 784 069 418 |
|
|
Selvita signs a drug discovery services contract with Rottapharm Madaus |
|
Tuesday, 20 July 2010 |
Rottapharm Madaus , the multinational pharmaceutical company, has signed a drug discovery research contract with Selvita - Poland based product and solution provider for the pharmaceutical and biotechnology industry.
Krakow, 20 July 2010 - Rottapharm Madaus and Selvita announced today signature of a services contract for delivery of drug discovery services. The aim of this project is to deliver to Rottapharm Madaus a set of designed and synthesized compounds, including their optimized synthesis route, which will have a therapeutic potential in an indicated area.
“We are delighted to start an FTE-based collaboration with Selvita. We are keen to take advantage of Selvita’s know-how to support the progression of our drug discovery pipeline – said Luigi Stasi, Rottapharm’s Director of Medicinal Chemistry Department. We are looking forward to a very fruitful and effective cooperation."
"We are very pleased and honoured that we can cooperate with such a prestigious multinational pharmaceutical company as Rottapharm Madaus – said Paweł Przewięźlikowski, Selvita’s CEO. This project is an immense chance for Selvita to show the great potential of our Computational Chemistry and Chemistry Departments. Working for Rottapharm Madaus on this project will enable us to take a full advantage of our highly skilled scientists and new facilities, and I truly believe we can deliver exactly what Rottapharm Madaus needs. I’m looking forward to this cooperation very much.”
Rottapharm is a multinational pharmaceutical company with Italian capital, established in Monza, Italy in 1961. Since its beginning, Rottapharm was characterized by a strong commitment to research: in almost 50 years, Rottapharm ‘s scientists synthesized thousands lead compounds on specific molecular targets, generating more than 300 patents and 19 original drugs. Rottapharm R&D is focused on therapeutic areas such as: rheumatology, gynaecology, urology, gastroenterology, bronchopneumology, psychiatry, oncology. In 2000, through the acquisition of major brands in intimate hygiene and paediatric care, such as the Saugella and Babygella brands, Rottapharm has entered the personal care market in the pharmacy, further strengthening its position thereafter. In 2007, Rottapharm performed the largest M & A transaction ever made by an Italian pharmaceutical company, through the acquisition of the German group Madaus Pharma.
Selvita Group is a Polish, privately-owned, biotechnology company engaged in the drug discovery, as well as in the drug discovery services. The company was established in 2007, and currently employs almost 100 scientists, including 33 PhDs. Since 2008, Selvita is also the main shareholder of BioCentrum, which provides in-vitro preclinical ADMET services, biochemistry services with special focus on protein engineering and antibody development. Selvita Group provides services in the following areas:
- Integrated drug discovery projects which include in silico modeling, and synthesis of a target-focused library, lead-optimization and preclinical development;
- Chemistry services, including contract synthesis, synthesis pathway design and optimization, analytical chemistry, as well as computational chemistry services;
- Biology services, including assay development such as ELISA and cytotoxicity assays, spectrophotometric, fluorescence and fluorescence anisotropy measurements, as well as cell cycle arrest analysis and apoptosis/necrosis identification; and
- Advanced protein modeling solutions, based on our proprietary protein modeling platform, as well as services in computational chemistry.
For more information about the project or the company, please contact:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
Media contact:
Natalia Pawela
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
mobile: 784 069 418 |
|
|
